

Minutes of the PHARMAC Consumer Advisory Committee (CAC) meeting

Wednesday 10 October 2018

The meeting was held on Level 6, 40 Mercer St, Wellington from 9.30 am.

Present

David Lui Chair

Stephanie Clare
Lisa Lawrence
Adrienne von Tunzelmann
Francesca Holloway
Neil Woodhams

CAC member
CAC member
CAC member
CAC member
CAC member

Apologies

Te Ropu Poa CAC member Tuiloma Lina Samu CAC member Key Frost CAC member

In attendance

Katie Sherriff (Acting CAC Secretary), Steve Maharey, Board Chair, Sarah Fitt, Chief Executive, Alison Hill, Director Engagement and Implementation, Michael Johnson, Director of Strategic Initiatives, Lloyd Quartermaine, Manager Communications and External Relations, Rebecca Elliott, Policy Manager (for relevant items).

1. Record of previous meeting

Minutes of the 5 July 2018 meeting were accepted as a true and accurate record.

Von Tunzelmann/Clare

2. Chair's report

The Chair commented on the importance of using members' community networks to support PHARMAC staff's engagement with – and understanding of - consumers. The Chair noted that making better use of existing networks will bring these perspectives and insights into discussions with staff. It would be useful to map CAC members' existing networks to identify overlaps and groups that are not currently represented by the Committee.

3. Matters arising

Two letters addressed to the Committee, and one letter written in response on behalf of the CAC Chair were noted.

Members commented that when responding to the public on behalf of CAC members, it should be explicitly explained that the Committee does not have a role in funding decisions.

Members asked that the process for responding to correspondence with members of the public be shared with the Committee.

Members also requested a session to explore how the Committee can engage with the public on behalf of PHARMAC.

4. Consumer voices review and CAC Terms of Reference workshop

CAC members discussed the outcomes of the 2018 Consumer Voices Review consultation, including the role and function of the Committee.

Members discussed learnings from the Community Conversations that PHARMAC could incorporate into future public consultations. These include making better use of CAC members' networks and knowledge about local venues, catering and timing of events.

Members discussed experiences of being on the Committee. Members noted that their understanding of PHARMAC is valuable in being able to explain PHARMAC's role to communities in a way that they can understand.

It was noted that although feedback about the role and function of the Committee received during consultation was limited, it is timely to look more fundamentally at the role and function of the Committee.

PHARMAC will commence a review of the Committee which members will have the opportunity to feed into in 2019. Members asked for another workshop on the role of the Committee at their next meeting.

5. Session with the Board Chair

Members congratulated Steve Maharey on his appointment as Chair of the PHARMAC Board.

The Board Chair thanked members for their contribution to PHARMAC and acknowledged the Committee's role advising PHARMAC on consumer perspectives. The Board Chair also discussed the opportunity for the Committee to represent and engage with groups PHARMAC is not currently reaching, such as Asian populations and new migrants.

The Board Chair commented on two trends he envisions CAC members providing perspectives to PHARMAC on; individualisation in peoples' expectations of health services, and new technologies.

The Board Chair noted that he will attend at least one CAC meeting per year.

6. Session with the Chief Executive

Members were thanked for attending PHARMAC's 25-year celebrations in July 2018.

PHARMAC is adopting the expression Te Pātaka Whaioranga (the storehouse of wellbeing) to be used alongside PHARMAC. PHARMAC is taking a staged approach to introducing Te Pātaka

Whaioranga, which will be launched in December 2018 when the Year in Review is produced. Members will be updated about plans to recognise the introduction of Te Pātaka Whaioranga.

It was noted that there has been a lot of consumer engagement regarding the venlafaxine brand change. It was also noted that there continues to be media activity and consumer engagement about access to cancer medicines.

7. Review of the Health and Disability system

Members participated in a session to consider PHARMAC's response to the Health and Disability Review. It was noted that while PHARMAC is not in scope of the Health and Disability review, PHARMAC's interactions with the health system are in scope.

Members will be updated on PHARMAC's response in March 2019.

Meeting closed 3.30 pm.